| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Z-Ile-Glu-Pro-Phe-OMe targets human cardiac chymase, a serine protease involved in the generation of angiotensin II and the degradation of extracellular matrix. It is a selective short peptide inhibitor of chymase. The compound inhibits the action of rat MAB elastase 2 on substrate Ang I with an IC50 of 49 µM.
|
|---|---|
| ln Vitro |
Z-Ile-Glu-Pro-Phe-OMe is a selective inhibitor of human cardiac chymase. It inhibits the action of rat MAB elastase 2 on substrate Ang I with an IC50 of 49 µM and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide with an IC50 of 4.8 µM. The compound is a short peptide inhibitor.
|
| ln Vivo |
Specific in vivo activity data for Z-Ile-Glu-Pro-Phe-OMe are not extensively reported in the available literature. As a chymase inhibitor, it may exhibit efficacy in preclinical models of cardiovascular disease and inflammation. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for Z-Ile-Glu-Pro-Phe-OMe typically involves measuring its inhibitory activity against chymase using a standard enzyme assay. The compound is incubated with the enzyme and a substrate, and the enzymatic activity is measured. The IC50 value is determined from the dose-response curve.
|
| Cell Assay |
The in vitro cellular assay for Z-Ile-Glu-Pro-Phe-OMe typically involves culturing relevant cell types (e.g., cardiac cells, mast cells) in appropriate growth media. Cells are treated with varying concentrations of the compound, and chymase activity or downstream signaling pathways are measured. The compound's effects on angiotensin II production and extracellular matrix degradation are assessed.
|
| Animal Protocol |
In vivo animal studies for Z-Ile-Glu-Pro-Phe-OMe would typically involve the use of rodent models of cardiovascular disease or inflammation. Animals would be administered the compound via appropriate routes (e.g., intravenous or intraperitoneal injection) at various dose levels. Parameters such as blood pressure, cardiac function, and inflammatory markers would be assessed.
|
| ADME/Pharmacokinetics |
Z-Ile-Glu-Pro-Phe-OMe has a molecular weight of 652.73 g/mol and a molecular formula of C34H44N4O9. The compound is also known as CH 5450. It should be stored under recommended conditions, typically shipped on blue ice. Further detailed physicochemical properties are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Z-Ile-Glu-Pro-Phe-OMe are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| Additional Infomation |
Z-Ile-Glu-Pro-Phe-OMe (CH 5450) is a selective short peptide inhibitor of human cardiac chymase. It inhibits the action of rat MAB elastase 2 on substrate Ang I with an IC50 of 49 µM and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide with an IC50 of 4.8 µM. The compound is used in research to study chymase inhibition. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C34H44N4O9
|
|---|---|
| Molecular Weight |
652.74
|
| Exact Mass |
652.31
|
| CAS # |
252557-97-4
|
| PubChem CID |
10032234
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
928.4±65.0 °C at 760 mmHg
|
| Flash Point |
515.3±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
4.22
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
47
|
| Complexity |
1070
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O=C([C@H](CCC(=O)O)NC([C@H]([C@@H](C)CC)NC(=O)OCC1C=CC=CC=1)=O)N1CCC[C@H]1C(N[C@H](C(=O)OC)CC1C=CC=CC=1)=O
|
| InChi Key |
NQFWNRFKRYMGAI-OXHJWIHTSA-N
|
| InChi Code |
InChI=1S/C34H44N4O9/c1-4-22(2)29(37-34(45)47-21-24-14-9-6-10-15-24)31(42)35-25(17-18-28(39)40)32(43)38-19-11-16-27(38)30(41)36-26(33(44)46-3)20-23-12-7-5-8-13-23/h5-10,12-15,22,25-27,29H,4,11,16-21H2,1-3H3,(H,35,42)(H,36,41)(H,37,45)(H,39,40)/t22-,25-,26-,27-,29-/m0/s1
|
| Chemical Name |
(4S)-5-[(2S)-2-[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-[[(2S,3S)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoic acid
|
| Synonyms |
ZIleGluProPheOMe; Z Ile Glu Pro Phe OMe; Z-Ile-Glu-Pro-Phe-OMe
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 43 mg/mL (~65.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5320 mL | 7.6600 mL | 15.3200 mL | |
| 5 mM | 0.3064 mL | 1.5320 mL | 3.0640 mL | |
| 10 mM | 0.1532 mL | 0.7660 mL | 1.5320 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
